Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 1019-1029

  Oulis, Panagiotis ^a   Konstantakopoulos, George ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Abuse potential; Alcohol dependence; Benzodiazepine dependence; Efficacy; Pregabalin; Relapse prevention; Safety; Side effects; Withdrawal syndrome

Indexed keywords

BENZODIAZEPINE; LORAZEPAM; NALTREXONE; PREGABALIN; TIAPRIDE;

ALCOHOLISM; ARTICLE; ATTENTION DISTURBANCE; BLURRED VISION; DIZZINESS; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MONOTHERAPY; PERIPHERAL EDEMA; QUALITY OF LIFE; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN;

ALCOHOLISM; ANIMALS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; GAMMA-AMINOBUTYRIC ACID; HUMANS; MOLECULAR STRUCTURE; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84862291441     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.685651     Document Type: Article

References (66)

1. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev 2011;6:CD008537
2. Minozzi S, Amato L, Vecchi S, et al. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2010;3:CD005064
3. Muzyk AJ, Fowler JA, Norwood DK, et al. Role of a2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother 2011;45:649-57
4. Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2011;1:CD008502
5. Jorgensen CH, Pedersen B, Tonnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011;35:1749-58
6. Hillemacher T, Heberlein A, Muschler MAN, et al. Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 2011;20:1073-86
7. Witkiewitz K, Saville K, Hamreus K. Acamposate for treatment of alcohol dependence: mechanisms, efficacy and clinical utility. Ther Clin Risk Manag 2012;8:45-53
8. Soyka M, Rosner S. Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs 2010;19:1451-8
9. Roache JD, Wang Y, Ait-Daoud N, et al. Prediction of serotonergic treatment-efficacy using age of onset and type A/B typologies of alcoholism. Alcohol Clin Exp Res 2008;32:1502-11
10. Kenna GA, Lomastro TL, Schiesl A, et al. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev 2009;2:135-42
11. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des 2010;16:2113-17
12. Martinotti G, Di Nicola M, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 2007;33:393-401 (Pubitemid 47037170)
13. Martinotti G, Di Nicola M, Di Giannantonio M. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial versus naltrexone. J Psychopharmacol 2009;23:123-9
14. Denis C, Fatseas M, Lavie E, et al. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005194
15. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006;7:2139-54
16. Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs 2006;20:685-93 (Pubitemid 44141496)
17. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (Barc) 2007;43:601-10 (Pubitemid 350004866)
18. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007;7:769-81 (Pubitemid 47037717)
19. Bandelow B, Zohar J, Hollander E, et al. WFSBP task force on treatment guidelines for anxiety, obsessive-compulsive and post-traumatic stress disorders. World J Biol Psychiatry 2008;9:248-312
20. Dooley DJ, Taylor CP, Donevan S, et al. Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82 (Pubitemid 46161838)
21. Li Z, Taylor CP, Weber M, et al. Pregabalin is a potent and selective ligand for a2d-1 and a2d-2 calcium channel subunits. Eur J Pharmacol 2011;667:80-90
22. Carlson JM, Greenberg T, Rubin D, et al. Feeling anxious: anticipatory amygdalo-insular response predicts the feeling of anxious anticipation. Soc Cogn Affect Neurosci 2011;6:74-81
23. Aupperle RL, Ravindran L, Tankersley D, et al. Pregabalin influences insula and amygdale activation during anticipation of emotional images. Neuropsychopharmacology 2011;36:1466-77.
24. Wang Z, Pang RD, Hernandez M, et al. Anxiolytic-like effect of pregabalin on unconditioned fear in the rat: an autoradiographic brain perfusion mapping and functional connectivity study. NeuroImage 2011; published online 1 December, doi:10.1016/j.neuroimage.2011.11.047.
25. Siok CJ, Taylor CP, Hajos M. Anxiolytic profile of pregabaline on elicited hippocampal theta oscillation. Neuropharmacology 2009;56:379-85.
26. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006;16(Suppl 2):S128-33 (Pubitemid 43947553)
27. Shneker BF, Mc Auley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005;39:2029-37 (Pubitemid 41745948)
28. Stopponi S, Somaini L, Cippitelli A, et al. Pragabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology 2011: published online 2 September 2011, doi:10.1007/s00213-011-2457-3
29. Becker HC, Myrick H, Veatch LM. Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol 2006;4:399-406
30. Martinotti G, Di Nicola M, Tedeschi D, et al. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008;25:608-18.
31. Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomized, double-blind, comparison trial. J Psychopharmacol 2010;24:1367-74.
32. Di Nicola M, Martinotti G, Tedeschi D, et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Hum Psychopharmacol Clin Exp 2010;25:268-75.
33. Martinotti G, Di Nicola M, Frustaci A, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-center, randomized, single-blind comparison trial. Addiction 2010;105:288-99.
34. Forg A, Hein J, Volkmar K, et al. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized, placebo-controlled trial. Alcohol Alcohol 2012:published online 2 January 2012, doi: 10.1093/alcalc/agr153.
35. Biermann T, Bleich S, Kornhuber J, et al. Pregabalin in benzodiazepine withdrawal. Pharmacopsychiatry 2007;40:292-3
36. Oulis P, Masdrakis VG, Karakatsanis NA, et al. Pregabalin in the discontinuation of long-term benzodiazaepine-use: a case series. Int Clin Psychopharmacol 2008;23:110-12 (Pubitemid 351317284)
37. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of benzodiazepine-use. Hum Psychopharmacol 2008;23:337-40.
38. Bramness JG, Sandvik P, Engeland A, et al. Does pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison withb gabapentin using the Norvegian prescription database. Basic Clin Pharmacol Toxicol 2010;107:88-6.
39. Bobes J, Rubio G, Teran A, et al. Pregabalin for the discontinuation of long-term benzodiazepine use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 2011, published online 18 February 2011, doi:10.1016/j.eurpsy.2010.12.004.
40. Rubio G, Bobes J, Cervera G, et al. Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use. Eur Addict Res 2011;17:262-70.
41. van Seventer R, Feister HA, Young JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in post-herpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84 (Pubitemid 44296762)
42. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2011, published online 21 June 2011, doi:10.1177/0269881111405360.
43. Oulis P, Nakkas G, Masdrakis VG. Pregabalin in Zolpidem Dependence and Withdrawal. Clin Neuropharm 2011;34:90-1.
44. Wustmann T, Piro J, Gutmann P. Metabolic considerations in a case of pregabalin-induced edema. Pharmacopsychiatry 2009;42:75-6
45. Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced hepatotoxicity. Ann Pharmacother 2011;45:e32
46. Einarsdottir S, Bjornsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008;20:1049
47. Dogan S, Ozberk S, Yursi A. Pregabalin-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2011;23:628
48. Anonymous. Abuse of pregabalin exists, but it's uncertain how often. Lakartidningen 2011;108:1501
49. Smith TL, Baldwin A, Cunningham LL, et al. Rash associated with pregabalin use. Ann Pharmacother 2008;42:1899-901
50. Zaccara G, Gangemi P, Perucca P, et al. The adverse event-profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36
51. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist 2005;70:43633-5
52. Raza S, Siddiqui UA, Megna JL, et al. Pregabalin treatment of anxiety in patients with substance use disorder. Ann Pharmacother 2010;44:937-8
53. Grosshans M, Mutschler J, Hermann D, et al. Pregabalin abuse, dependence and withdrawal: a case-report. Am J Psychiatry 2010;167:869
54. Filipetto FA, Zipp CP, Cohen JS. Potential of pregabalin abuse or diversion after past drug-seeking behavior: case-report. JAOA 2010;110:605-7
55. Yargic I, Ozdemiroglu FA. Pragabalin abuse: a case-report. Bull Clin Psychopharmacol 2011;21:64-6
56. Landmark CJ, Fossmark H, Larson PG, et al. The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen 2011;131:223
57. Westin AA, Strom EJ. Yes, pregabalin can be abused! Tidsskr Nor Laegeforen 2010;130:2108
58. Bramness JG. Abuse of pregabalin. Tidsskr Nor Laegeforen 2010;130:1703-4
59. Chalabianloo F, Scjott J. Abuse of pregabalin. Tidsskr Nor Laegeforen 2009;129:186-7
60. Schifano F, Leoni M, Martinotti G, et al. Importance of cyberspace for the assessment of the drug-abuse market: preliminary results from the Psychonaut 2002 project. Cberpsychol Behav 2003;6:405-10 (Pubitemid 37087683)
61. Schifano F, Deluca P, Agosti L, et al. New trends in the cyber and street market of recreational drugs? The case of 2C-T-7 ("Blue Mystic"). J Psychopharmacol 2005;19:675-9 (Pubitemid 41578831)
62. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011;80:118-22.
63. Schwan S, Sundstroem A, Stjernberg E, et al. A signal for an abuse liability for pregabalin: results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010;66:947-53.
64. Zacny JP, Paice JA, Calson DW. Subjective, psychomotor and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 2012;100:560-5
65. Hindmarch I, Trick L, Ridout F. A double-blind, placebo-and positive-internal controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacology 2005;183:133-43 (Pubitemid 41609265)
66. Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010;74:755-61